02.02.11 - Apria Healthcare Signs Definitive Asset Purchase Agreement to Acquire United States Homecare Business of Praxair, Inc.
Apria Healthcare Group Inc. (“Apria Healthcare” or “Apria”), Praxair, Inc. (NYSE: PX) and Praxair Healthcare Services, Inc. (collectively, “Praxair”), jointly announced today that Apria Healthcare’s wholly owned subsidiary, Apria Healthcare, Inc. (“AHI”) and Praxair have entered into a definitive asset purchase agreement whereby AHI will acquire the assets of Praxair’s home healthcare services division in the United States. The terms of the agreement were not disclosed.  The transaction is expected to close during the first quarter of 2011, subject to satisfaction of customary terms and conditions.

“We look forward to welcoming the Praxair patients, customers and employees into Apria’s home respiratory services division,” said Norman C. Payson, MD, Apria’s Chairman and Chief Executive Officer.  “The acquisition expands Apria’s service offering in several key states and enhances our prospects for both traditional and managed care growth in future years.”

12.20.2010 - International Scholarship and Tuition Services, Inc. Will Provide Full Service Management of Coram's New Scholarship Program
International Scholarship and Tuition Services, Inc. (ISTS) recently signed a three-year agreement with Coram Specialty Infusion Services to manage application processing and funds disbursement for their new Together Forward scholarship program.

The Together Forward scholarship program, launching January 1, 2011, will award four renewable $2,500 scholarships to individuals living with a bleeding disorder such as hemophilia. Hemophilia is a rare, genetic blood clotting disorder affecting about 18,000 people in the United States – almost exclusively males. The transition to college is an important step for anyone, but for someone with hemophilia there is the added responsibility of being newly independent and caring for their chronic illness. Coram is excited to support these students through this new scholarship program in hopes that it will encourage them to pursue higher education.

12.01.2010 - Apria Healthcare Names New Chief Operating Officer
LAKE FOREST, CA. December 1, 2010 — Apria Healthcare Group Inc. today announced the appointment of Daniel E. Greenleaf to the position of Chief Operating Officer. In this capacity, Mr. Greenleaf will be responsible for leading the operations and sales functions of both the home infusion therapy and home respiratory therapy/home medical equipment segments of the Company.

Mr. Greenleaf has served since April 2008 as President of Apria's Home Infusion Therapy segment, a position he will continue to hold. Prior to joining Apria, he served as President and Chief Executive Officer of VioQuest Pharmaceuticals, Inc., a New Jersey-based biopharmaceutical company.

07.25.2009 - Medicare Part B — Let Your Voice Be Heard
Did you know that Medicare does not provide coverage for certain home infusion therapies under Medicare Part B? Medicare D, the pharmacy benefit plan, limits coverage to the infusion drug only and does not cover the clinical services (pharmacy, nursing, and supplies), that are required. As a result, Medicare patients have no choice but to receive treatment from hospitals, doctor’s offices and skilled nursing facilities, where they pay less in out-of-pocket expenses than if their coverage were similar to the commercially insured in the home. This adds unnecessary expense to the healthcare system, reduces patient choice, and inhibits delivery system reform.

Our national representatives need to understand the impact of this lack of coverage. By providing this benefit, they would be supporting cost reductions in the Medicare A program and more importantly, support patients who wish to reside in the setting that is most comfortable for therapy – home.

04.07.2008 - Apria Healthcare Names New President of Coram
Apria Healthcare Group Inc. (NYSE:AHG) today announced the appointment of Daniel E. Greenleaf to lead its Coram Specialty Infusion Services division as President, replacing John Arlotta, who, as previously announced during Apria's December 2007 acquisition of Coram, Inc., is scheduled to depart the organization in June 2008. Mr. Greenleaf will be based in the Coram division office located in Denver, Colorado.

Mr. Greenleaf most recently served as President and Chief Executive Officer of VioQuest Pharmaceuticals, Inc., a New Jersey-based biopharmaceutical company focused on the acquisition, development and commercialization of oncology drug therapies, from 2005 to 2007.

12.03.2007 - Apria Healthcare Completes Purchase of Coram, Inc.
Apria Healthcare Group Inc. (“Apria Healthcare” or “Apria”) (NYSE:AHG) today announced that it has completed its acquisition of Coram, Inc. (“Coram”) for a cash purchase price of $350 million. Coram provides a comprehensive range of home infusion therapies and specialty pharmaceuticals to 65,000 patients through a network of more than 70 home infusion branches across the country, 50 company-owned and operated ambulatory infusion suites and 2,100 employees.

“We are excited about the opportunities associated with the Coram acquisition,” said Lawrence M. Higby, Apria’s Chief Executive Officer. “Strategically, it transforms the company by diversifying our product and payor mix and positioning us favorably in the rapidly growing specialty pharmaceutical and infusion markets. From a customer perspective, we believe it offers a number of expanded clinical and integrated homecare solutions to patients, physicians and payors alike. Now that the transaction is complete, we will begin implementing our integration plans, and look forward to realizing the strategic and financial synergies that this transaction creates for Apria in 2008 and beyond.”

10.15.2007 - Apria Healthcare Signs Definitive Agreement to Acquire Coram, Inc.

• Acquisition significantly expands Apria's national infusion footprint and adds broad network of ambulatory infusion suites to Apria's existing service offering
• Adds strength in fast-growing specialty pharmacy services segment
• Expands managed care service capabilities; diversifies payor and product mix
• Creates the premier specialty infusion services provider
  

7.24.2007 - Coram Now Providing Soliris™ Infusions
Coram has announced that it has become an approved provider of Soliris™ for Alexion Pharmaceuticals, Inc. Soliris is the first and only therapy approved for paroxysmal nocturnal hemoglobinuria, or PNH, a rare, disabling and life-threatening blood disorder characterized by chronic red blood cell destruction, otherwise known as hemolysis.

› News Archive

To learn more about Coram, contact us. To enroll or refer a patient to Coram, click here.